236 related articles for article (PubMed ID: 30207285)
21. p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells.
Vogl FD; Stickeler E; Weyermann M; Köhler T; Grill HJ; Negri G; Kreienberg R; Runnebaum IB
Oncology; 1999 Nov; 57(4):324-9. PubMed ID: 10575320
[TBL] [Abstract][Full Text] [Related]
22. Development of a multimarker assay for early detection of ovarian cancer.
Yurkovetsky Z; Skates S; Lomakin A; Nolen B; Pulsipher T; Modugno F; Marks J; Godwin A; Gorelik E; Jacobs I; Menon U; Lu K; Badgwell D; Bast RC; Lokshin AE
J Clin Oncol; 2010 May; 28(13):2159-66. PubMed ID: 20368574
[TBL] [Abstract][Full Text] [Related]
23. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.
Shadfan BH; Simmons AR; Simmons GW; Ho A; Wong J; Lu KH; Bast RC; McDevitt JT
Cancer Prev Res (Phila); 2015 Jan; 8(1):37-48. PubMed ID: 25388014
[TBL] [Abstract][Full Text] [Related]
24. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
[No Abstract] [Full Text] [Related]
25. Ultrasensitive immunoassay of carcinoma antigen 125 in untreated human plasma samples using gold nanoparticles with flower like morphology: A new platform in early stage diagnosis of ovarian cancer and efficient management.
Hasanzadeh M; Sahmani R; Solhi E; Mokhtarzadeh A; Shadjou N; Mahboob S
Int J Biol Macromol; 2018 Nov; 119():913-925. PubMed ID: 30081127
[TBL] [Abstract][Full Text] [Related]
26. Autoantibody biomarkers for the detection of serous ovarian cancer.
Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
[TBL] [Abstract][Full Text] [Related]
27. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
[TBL] [Abstract][Full Text] [Related]
28. Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.
Pedersen JW; Gentry-Maharaj A; Nøstdal A; Fourkala EO; Dawnay A; Burnell M; Zaikin A; Burchell J; Papadimitriou JT; Clausen H; Jacobs I; Menon U; Wandall HH
Int J Cancer; 2014 May; 134(9):2180-88. PubMed ID: 24122770
[TBL] [Abstract][Full Text] [Related]
29. Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping Indicates Increased Binding to Cytoplasmic Domains of CXCR3.
Recke A; Regensburger AK; Weigold F; Müller A; Heidecke H; Marschner G; Hammers CM; Ludwig RJ; Riemekasten G
Front Immunol; 2018; 9():428. PubMed ID: 29623076
[TBL] [Abstract][Full Text] [Related]
30. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876
[TBL] [Abstract][Full Text] [Related]
31. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
[TBL] [Abstract][Full Text] [Related]
32. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
Taylor DD; Gercel-Taylor C; Parker LP
Gynecol Oncol; 2009 Oct; 115(1):112-120. PubMed ID: 19647308
[TBL] [Abstract][Full Text] [Related]
33. Human Blood Autoantibodies in the Detection of Colorectal Cancer.
Negm OH; Hamed MR; Schoen RE; Whelan RL; Steele RJ; Scholefield J; Dilnot EM; Shantha Kumara HM; Robertson JF; Sewell HF
PLoS One; 2016; 11(7):e0156971. PubMed ID: 27383396
[TBL] [Abstract][Full Text] [Related]
34. Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes.
Vennegoor CJ; Nijman HW; Drijfhout JW; Vernie L; Verstraeten RA; von Mensdorff-Pouilly S; Hilgers J; Verheijen RH; Kast WM; Melief CJ; Kenemans P
Cancer Lett; 1997 Jun; 116(1):93-101. PubMed ID: 9177463
[TBL] [Abstract][Full Text] [Related]
35. Autoantibody biomarkers in the detection of cancer.
Cho-Chung YS
Biochim Biophys Acta; 2006 Jun; 1762(6):587-91. PubMed ID: 16730166
[TBL] [Abstract][Full Text] [Related]
36. Plasma Autoantibodies Associated with Basal-like Breast Cancers.
Wang J; Figueroa JD; Wallstrom G; Barker K; Park JG; Demirkan G; Lissowska J; Anderson KS; Qiu J; LaBaer J
Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1332-40. PubMed ID: 26070530
[TBL] [Abstract][Full Text] [Related]
37. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
[TBL] [Abstract][Full Text] [Related]
38. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA.
Zhang Q; Hu G; Yang Q; Dong R; Xie X; Ma D; Shen K; Kong B
Gynecol Oncol; 2013 Jul; 130(1):132-9. PubMed ID: 23623832
[TBL] [Abstract][Full Text] [Related]
39. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.
Vogl FD; Frey M; Kreienberg R; Runnebaum IB
Br J Cancer; 2000 Nov; 83(10):1338-43. PubMed ID: 11044359
[TBL] [Abstract][Full Text] [Related]
40. Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer.
Qiu C; Duan Y; Wang B; Shi J; Wang P; Ye H; Dai L; Zhang J; Wang X
Front Immunol; 2021; 12():698312. PubMed ID: 34489945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
